Top Page
Aroa Biosurgery Ltd
(Sydney:ARX)
Aroa Biosurgery Ltd (ARX) vs. iShares MSCI Australia ETF (EWA)
Aroa Biosurgery Ltd Business Overview & Revenue Model
Aroa Biosurgery Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.15M | 76.97M | 63.36M | 59.31M | 36.88M | 20.51M |
| Gross Profit | 66.15M | 65.99M | 54.10M | 50.06M | 28.17M | 14.25M |
| EBITDA | 486.58K | 2.65M | -6.78M | 3.24M | -3.75M | -7.05M |
| Net Income | -3.49M | -3.47M | -9.75M | -370.68K | -7.79M | -17.63M |
Balance Sheet | ||||||
| Total Assets | 98.94M | 98.94M | 101.88M | 109.07M | 104.71M | 73.12M |
| Cash, Cash Equivalents and Short-Term Investments | 20.13M | 20.13M | 27.73M | 43.00M | 53.35M | 33.93M |
| Total Debt | 5.83M | 5.83M | 6.82M | 6.65M | 5.46M | 14.90M |
| Total Liabilities | 14.35M | 14.35M | 14.79M | 13.69M | 11.30M | 19.43M |
| Stockholders Equity | 84.59M | 84.59M | 87.08M | 95.38M | 93.40M | 53.69M |
Cash Flow | ||||||
| Free Cash Flow | -4.48M | -5.69M | -10.00M | -10.66M | -15.39M | -6.05M |
| Operating Cash Flow | -2.37M | -2.33M | -6.76M | -3.53M | -10.86M | -4.68M |
| Investing Cash Flow | 444.62K | 273.54K | 9.31M | 6.79M | -32.41M | -19.74M |
| Financing Cash Flow | -2.00M | -1.34M | -948.41K | -471.78K | 34.98M | 34.06M |
Aroa Biosurgery Ltd Technical Analysis
Aroa Biosurgery Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $18.36B | 47.23 | 20.11% | 1.51% | 4.32% | 9.24% | |
61 Neutral | AU$274.30M | -78.71 | -4.06% | ― | 20.36% | 64.81% | |
58 Neutral | $891.19M | 67.54 | 16.49% | ― | 23.31% | 151.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$73.35M | -5.46 | -31.98% | ― | 34.20% | -23.90% |
Aroa Biosurgery Ltd Corporate Events
Aroa Biosurgery Ltd has released its Q2 quarterly cashflow report, emphasizing its commitment to advancing regenerative healing technologies. The announcement, while not a prospectus or an offer of securities, serves to educate investors about the company’s financial performance and strategic direction. This release could impact the company’s market positioning by highlighting its ongoing efforts in innovation and product development, potentially influencing stakeholder perceptions and investment decisions.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited reported positive financial performance for the quarter ending September 2025, with a net cash flow of NZ$2.1 million and cash receipts of NZ$23.5 million. The company achieved its highest sales quarter for the Myriad product line and published eight new peer-reviewed studies, enhancing its clinical credibility. A proposed US reimbursement policy change could benefit Aroa’s Symphony product, potentially improving its market positioning. The company plans to release its H1 FY26 results in November and will host an investor event in Sydney.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced it will host a webinar to discuss its September quarterly results, featuring CEO Brian Ward and CFO James Agnew. This event signifies the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the cessation of several securities, including restricted stock units, options, and performance rights, due to unmet conditions or expiry without exercise. This update reflects adjustments in the company’s issued capital and may impact stakeholders’ perception of the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in the director’s interest notice, specifically regarding Brian Ward’s indirect interest in the company’s securities. The update reveals an increase in performance share rights, which were issued following shareholder approval at the recent Annual General Meeting. This change reflects the company’s ongoing commitment to aligning its leadership’s interests with shareholder value and could potentially impact its market positioning by strengthening stakeholder confidence.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced the issuance of 1,051,869 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize and retain key employees, potentially impacting its operational efficiency and competitive positioning in the biosurgery market.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced the results of its Annual General Meeting, where all resolutions were carried, including the re-election of Mr. James McLean, approval of auditor’s remuneration, issuance of equity securities under the Aroa Omnibus Incentive Plan, and the issuance of long-term incentives to CEO Brian Ward. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic initiatives, reinforcing its position in the soft tissue regeneration industry.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has released a presentation intended for investor education, emphasizing that it is not an offer of securities or a prospectus. The presentation includes forward-looking statements about the company’s future performance, which are based on current expectations and assumptions. Stakeholders are advised to consider these statements with caution due to their inherent uncertainty and the subjective judgments involved.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery reported a successful fiscal year with a 23% growth in business, increased margins, and efficient cash management, alongside three consecutive quarters of positive cash flow. The company anticipates continued growth despite new US tariffs, leveraging expanding sales in Europe and other markets. Clinical studies have reinforced the efficacy of AROA ECM products, emphasizing their value in reducing hospital stays and improving patient outcomes. Product development included enhancements to the Ovitex range and the ongoing commercialization of Enivo technology, aimed at addressing unmet clinical needs. TELA Bio remains a strategic partner, contributing to Aroa’s cash flow and market presence, although market sentiment towards TELA Bio has been mixed.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced its upcoming Annual General Meeting (AGM) scheduled for August 20, 2025, which will be conducted as a hybrid meeting allowing both physical and online attendance. The meeting will cover several key items including the board chair’s and CEO’s addresses, consideration of financial results, and resolutions on director re-election, auditor’s remuneration, and the issuance of equity securities under the Aroa Omnibus Incentive Plan. This AGM is significant for stakeholders as it includes important resolutions that could impact the company’s governance and financial strategies.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd released its quarterly report for Q1 FY26, emphasizing its commitment to unlocking regenerative healing. The report, intended for investor education, highlights the company’s strategic direction and market positioning, although it does not serve as a prospectus or an offer of securities. The company cautions that past performance is not indicative of future outcomes and includes forward-looking statements that are subject to change.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced its third consecutive quarter of positive net cash flow, with operating cash flow reaching NZ$1.7 million and strong customer cash receipts of NZ$22.5 million. The company reaffirmed its FY26 revenue guidance of NZ$92-100 million and normalised EBITDA of NZ$5-8 million, indicating a growth trajectory. The company also highlighted the sustained growth of its Myriad product line and the publication of two new peer-reviewed clinical studies, reinforcing the efficacy of its ECM technology. These developments are expected to strengthen Aroa’s market position and provide significant value to stakeholders.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced a change in the director’s interest, specifically involving Phillip McCaw. The change entails the lapse of 81,925 options due to expiry, impacting McCaw’s indirect holdings through various trusts. This adjustment reflects routine portfolio management and does not indicate any immediate strategic shifts for the company.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited announced a change in the interests of its director, John Pinion, as per the latest notice to the ASX. The change involved the lapse of 245,775 options exercisable at $0.75 due to expiry, which impacts the director’s holdings but does not alter the number of fully paid ordinary shares held. This update reflects routine adjustments in director holdings, which are part of standard corporate governance practices, and is unlikely to have significant implications for the company’s operations or market position.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically involving the lapse of options due to expiry. This change reflects a reduction in the number of options held by Director James McLean, which may impact his financial stake in the company but does not affect the overall number of fully paid ordinary shares he holds. Such changes are routine and part of the company’s regulatory compliance, with no immediate implications for stakeholders or the company’s market position.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically noting the lapse of 3,132,525 options held by Director Brian Ward due to their expiry on July 23, 2025. This change reflects a reduction in Ward’s indirect holdings, which may impact the company’s governance dynamics and stakeholder perceptions, although it does not involve any financial consideration.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the cessation of 5,104,050 securities due to the expiry of options without exercise or conversion as of July 23, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.